Abstract
Yes-associated protein (YAP) is a key oncogene in the Hippo tumor suppression pathway, historically challenging to target due to its intrinsically disordered nature. Leveraging recent advances in high-throughput screening that identified several YAP binders, we employed proteolysis-targeting chimera technology to develop a series of YAP degraders. Utilizing NSC682769, a known YAP binder, linked with VHL ligand 2 or pomalidomide via diverse linkers, we synthesized degraders including YZ-6. This degrader not only recruits the E3 ligase VHL for the rapid and sustained degradation of YAP but also effectively inhibits its nuclear localization, curtailing YAP/TEAD-mediated transcription in cancer cell lines such as NCI-H226 and Huh7. This dual action significantly diminishes YAP's oncogenic activity, contributing to the potent antiproliferative effects observed both in vitro and in a Huh7 xenograft mouse model. These results underscore the potential of PROTAC-mediated YAP degradation as a strategy for treating YAP-driven cancers.
MeSH terms
-
Adaptor Proteins, Signal Transducing* / metabolism
-
Animals
-
Antineoplastic Agents / chemical synthesis
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / metabolism
-
Antineoplastic Agents / pharmacology
-
Cell Line, Tumor
-
Cell Proliferation / drug effects
-
Humans
-
Intrinsically Disordered Proteins / chemistry
-
Intrinsically Disordered Proteins / metabolism
-
Mice
-
Mice, Nude
-
Proteolysis Targeting Chimera
-
Proteolysis* / drug effects
-
Thalidomide / analogs & derivatives
-
Thalidomide / chemical synthesis
-
Thalidomide / chemistry
-
Thalidomide / pharmacology
-
Transcription Factors* / antagonists & inhibitors
-
Transcription Factors* / metabolism
-
Von Hippel-Lindau Tumor Suppressor Protein / metabolism
-
Xenograft Model Antitumor Assays
-
YAP-Signaling Proteins* / metabolism
Substances
-
Transcription Factors
-
Adaptor Proteins, Signal Transducing
-
YAP-Signaling Proteins
-
Von Hippel-Lindau Tumor Suppressor Protein
-
YAP1 protein, human
-
Intrinsically Disordered Proteins
-
Thalidomide
-
pomalidomide
-
Antineoplastic Agents
-
VHL protein, human
-
Proteolysis Targeting Chimera